121 results on '"Elvin, Julia A."'
Search Results
2. BRCA1/2 reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy.
3. POLE variant phenotypic classification to enable identification of patients with colorectal cancer (CRC) who may benefit from immune checkpoint inhibition (ICI).
4. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit
5. Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study.
6. Landscape of homologous recombination reversion mutations in gynecologic malignancies.
7. Mutational landscape of low-grade serous carcinoma of the ovary.
8. Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network.
9. Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race.
10. Racial differences in the mutational landscape of serous endometrial cancer.
11. Landscape of homologous recombination reversion mutations in pancreaticobiliary malignancies.
12. Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
13. Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma
14. TCF-001 TRACK (Target Rare Cancer Knowledge): A national patient-centric precision oncology trial for rare cancers.
15. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
16. CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1–Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion
17. Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms
18. Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV– Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets
19. Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial.
20. Differential genomic landscape of clinically advanced/metastatic chordomas (mChor) based on primary tumor site.
21. Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).
22. Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): A comparative comprehensive genomic profiling (CGP) study.
23. Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study.
24. Primary adult retroperitoneal sarcoma (RS): Comprehensive genomic profiling (CGP) study.
25. Clinically advanced renal cell carcinoma (RCC) and renal sarcoma (RSC) in young patients: A comprehensive genomic profiling (CGP) study.
26. Contrasting genomic profiles in post-systemic treatment metastatic sites (MET), pretreatment primary tumors (PT), and liquid biopsies (LB) of clinically advanced prostate cancer (PC).
27. Acquired RB1 mutations in estrogen receptor-positive (ER+) clinically advanced and metastatic breast cancer (MBC).
28. Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.
29. NF2 mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study.
30. Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).
31. Comprehensive genomic profiling (CGP) in post-systemic treatment (Post) metastatic sites (MET) and pretreatment (Pre) primary tumors (PT) of metastatic prostate cancer (mPC).
32. Metastatic renal cell carcinoma (mRCC) in young patients: A comprehensive genomic profiling (CGP) study.
33. The emerging target KRAS G12C in genitourinary malignancies.
34. PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas.
35. Primary versus metastatic intrahepatic cholangiocarcinoma: A comparative comprehensive genomic profiling (CGP) study.
36. Malignant pheochromocytoma (MP): A comprehensive genomic profiling (CGP) study.
37. Mutational landscape of ovarian cancers (OC) identified by prospective clinical sequencing in a nationwide cancer network.
38. Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study.
39. Anal melanoma: A comparative comprehensive genomic profiling study.
40. FGFR2: A pan-genomic target.
41. Mutational landscape of endometrial cancer identified by prospective clinical sequencing in a nationwide cancer network.
42. Ductal (PDC), acinar (PAC) and neuroendocrine (PNC) carcinomas of the prostate: A comparative comprehensive genomic profiling (CGP) study.
43. Mutational landscape of cervical cancer identified by prospective clinical sequencing in a nationwide cancer network.
44. Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Profiling (CGP) Study.
45. Immunotherapy predictive biomarkers in metastatic breast cancer (MBC).
46. Extra-mammary Paget’s disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.
47. Penile and uterine cervical squamous cell carcinomas: A comparative genomic profiling study.
48. Malignant pheochromocytoma: A comprehensive genomic profiling study.
49. Genomic features of metastatic testicular sex cord stromal tumors.
50. Ductal and acinar carcinomas of the prostate: A comparative comprehensive genomic profiling study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.